Cystic fibrosis biotech Proteostasis Therapeutics files for an $86 million IPO

Shutterstock photo

Proteostasis Therapeutics, which is developing combination therapeutics that use amplifier molecules to modulate proteins, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.

The Cambridge, MA-based company, which was founded in 2006 and booked $4 million in sales for the 12 months ended September 30, 2015, plans to list on the Nasdaq under the symbol PTI. Proteostasis Therapeutics filed confidentially on 5/8/2015. Leerink Partners, RBC Capital Markets, Baird and H.C. Wainwright are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Cystic fibrosis biotech Proteostasis Therapeutics files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.